Related Experiment Video

Updated: May 16, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Low expression of SHP-2 is associated with less favorable prostate cancer outcomes

Helena Tassidis1, Leon J S Brokken, Karin Jirström

  • 1Department of Laboratory Medicine, Division of Tumor Biology, Lund University, Lund, Sweden.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|November 30, 2012
PubMed

Insights

Low cytoplasmic expression of Src homology 2 domain-containing tyrosine phosphatase-2 (SHP-2) in prostate cancer cells correlates with poorer patient outcomes, including increased recurrence and progression. This suggests SHP-2 plays a role in controlling tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Src homology 2 domain-containing tyrosine phosphatase-2 (SHP-2) is a key regulator of cellular signaling pathways.
  • SHP-2 dephosphorylates growth factor receptors and associated tyrosine-phosphorylated proteins, influencing cell growth and differentiation.

Purpose of the Study:

  • To investigate the expression and clinical significance of SHP-2 in prostate cancer.
  • To determine the correlation between SHP-2 expression levels and prostate cancer characteristics and patient outcomes.

Main Methods:

  • Analysis of SHP-2 protein expression in four prostate cancer cell lines (PC3, DU145, LNCaP, LNCaP-IL6+).
  • Tissue microarray analysis of SHP-2 expression in tumor specimens from 122 prostate cancer patients.
  • Correlation of SHP-2 staining intensity and localization (cytoplasmic vs. nuclear) with clinicopathological parameters and patient outcomes (biochemical recurrence, clinical progression).

Main Results:

  • All four prostate cancer cell lines expressed SHP-2 protein.
  • Low cytoplasmic SHP-2 expression inversely correlated with prostate volume.
  • Nuclear SHP-2 staining positively correlated with extracapsular extension.
  • Low SHP-2 expression in post-prostatectomy specimens was associated with unfavorable outcomes, including higher rates of biochemical recurrence and clinical progression.

Conclusions:

  • SHP-2 is expressed in prostate cancer cells.
  • Loss of cytoplasmic SHP-2 expression is linked to increased tumor growth and progression.
  • SHP-2 expression levels may serve as a prognostic biomarker for prostate cancer patients.

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...